Cargando…
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation
Colorectal cancer (CRC), the second leading cause of cancer-related deaths in the US, has been treated with targeted therapies. However, the mechanisms of differential responses and resistance of CRCs to targeted therapies are not well understood. In this study, we found that genetic alterations of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226932/ https://www.ncbi.nlm.nih.gov/pubmed/27399335 http://dx.doi.org/10.1038/onc.2016.247 |
_version_ | 1782493729128448000 |
---|---|
author | Tong, Jingshan Tan, Shuai Zou, Fangdong Yu, Jian Zhang, Lin |
author_facet | Tong, Jingshan Tan, Shuai Zou, Fangdong Yu, Jian Zhang, Lin |
author_sort | Tong, Jingshan |
collection | PubMed |
description | Colorectal cancer (CRC), the second leading cause of cancer-related deaths in the US, has been treated with targeted therapies. However, the mechanisms of differential responses and resistance of CRCs to targeted therapies are not well understood. In this study, we found that genetic alterations of FBW7, an E3 ubiquitin ligase and a tumor suppressor frequently mutated in CRCs, contribute to resistance to targeted therapies. CRC cells containing FBW7 inactivating mutations are insensitive to clinically used multi-kinase inhibitors of RAS/RAF/MEK/ERK signaling, including regorafenib and sorafenib. In contrast, sensitivity to these agents is not affected by oncogenic mutations in KRAS, BRAF, PIK3CA, or p53. These cells are defective in apoptosis due to blocked degradation of Mcl-1, a pro-survival Bcl-2 family protein. Deleting FBW7 in FBW7-wild-type CRC cells abolishes Mcl-1 degradation and recapitulates the in vitro and in vivo drug resistance phenotypes of FBW7-mutant cells. CRC cells selected for regorafenib resistance have progressive enrichment of pre-existing FBW7 hotspot mutations, and are cross-resistant to other targeted drugs that induce Mcl-1 degradation. Furthermore, a selective Mcl-1 inhibitor restores regorafenib sensitivity in CRC cells with intrinsic or acquired resistance. Together, our results demonstrate FBW7 mutational status as a key genetic determinant of CRC response to targeted therapies, and Mcl-1 as an attractive therapeutic target. |
format | Online Article Text |
id | pubmed-5226932 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
record_format | MEDLINE/PubMed |
spelling | pubmed-52269322017-01-12 FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation Tong, Jingshan Tan, Shuai Zou, Fangdong Yu, Jian Zhang, Lin Oncogene Article Colorectal cancer (CRC), the second leading cause of cancer-related deaths in the US, has been treated with targeted therapies. However, the mechanisms of differential responses and resistance of CRCs to targeted therapies are not well understood. In this study, we found that genetic alterations of FBW7, an E3 ubiquitin ligase and a tumor suppressor frequently mutated in CRCs, contribute to resistance to targeted therapies. CRC cells containing FBW7 inactivating mutations are insensitive to clinically used multi-kinase inhibitors of RAS/RAF/MEK/ERK signaling, including regorafenib and sorafenib. In contrast, sensitivity to these agents is not affected by oncogenic mutations in KRAS, BRAF, PIK3CA, or p53. These cells are defective in apoptosis due to blocked degradation of Mcl-1, a pro-survival Bcl-2 family protein. Deleting FBW7 in FBW7-wild-type CRC cells abolishes Mcl-1 degradation and recapitulates the in vitro and in vivo drug resistance phenotypes of FBW7-mutant cells. CRC cells selected for regorafenib resistance have progressive enrichment of pre-existing FBW7 hotspot mutations, and are cross-resistant to other targeted drugs that induce Mcl-1 degradation. Furthermore, a selective Mcl-1 inhibitor restores regorafenib sensitivity in CRC cells with intrinsic or acquired resistance. Together, our results demonstrate FBW7 mutational status as a key genetic determinant of CRC response to targeted therapies, and Mcl-1 as an attractive therapeutic target. 2016-07-11 2017-02-09 /pmc/articles/PMC5226932/ /pubmed/27399335 http://dx.doi.org/10.1038/onc.2016.247 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Tong, Jingshan Tan, Shuai Zou, Fangdong Yu, Jian Zhang, Lin FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation |
title | FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation |
title_full | FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation |
title_fullStr | FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation |
title_full_unstemmed | FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation |
title_short | FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation |
title_sort | fbw7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking mcl-1 degradation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226932/ https://www.ncbi.nlm.nih.gov/pubmed/27399335 http://dx.doi.org/10.1038/onc.2016.247 |
work_keys_str_mv | AT tongjingshan fbw7mutationsmediateresistanceofcolorectalcancertotargetedtherapiesbyblockingmcl1degradation AT tanshuai fbw7mutationsmediateresistanceofcolorectalcancertotargetedtherapiesbyblockingmcl1degradation AT zoufangdong fbw7mutationsmediateresistanceofcolorectalcancertotargetedtherapiesbyblockingmcl1degradation AT yujian fbw7mutationsmediateresistanceofcolorectalcancertotargetedtherapiesbyblockingmcl1degradation AT zhanglin fbw7mutationsmediateresistanceofcolorectalcancertotargetedtherapiesbyblockingmcl1degradation |